^

Association details:

Evidence:

Evidence Level:
Sensitive: C3 – Early Trials
New
Title:
First-in-human Phase 1 Study of MORAb-202, An Antibody-drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-a-positive Advanced Solid Tumors
Published date:
04/29/2021
Excerpt:
FRα-positive solid tumors who failed to respond to standard therapy were eligible. Patients received MORAb-202...Complete response, partial response, and stable disease were observed in one, nine, and eight patients, respectively....MORAb-202 demonstrated promising antitumor activity in FRα-positive solid tumors...
DOI:
10.1158/1078-0432.CCR-20-4740
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our